Top Suppliers:I want be here
Related CAS#:
54-25-1 27089-56-1
56707-91-6 37113-42-1
20500-29-2 10592-61-7
2169-64-4 14048-22-7
100297-31-2 6198-30-7
1823951-94-5 1337139-69-1
1158522-08-7 940364-43-2
523992-33-8 134104-43-1
131615-57-1 1424369-06-1
6906-52-1 930439-75-1

54-25-1

54-25-1 structure
54-25-1 structure
  • Name: 6-AZAURIDINE
  • Chemical Name: 6-azauridine
  • CAS Number: 54-25-1
  • Molecular Formula: C8H11N3O6
  • Molecular Weight: 245.19
  • Catalog: Biochemical Nucleoside drugs Nucleoside intermediate
  • Create Date: 2018-04-18 08:00:00
  • Modify Date: 2024-01-03 11:42:50
  • 6-Azuridine (6-Azauridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
Name 6-azauridine
Synonyms 6-azur
AZURIDINE
ribo-azuracil
6-azuridine
6-AZAURIDINE
6-aza-uridine
6-Azauracil Ribozide
MFCD00006472
1,2,4-Triazine-3,5(2H,4H)-dione, 2-β-D-ribofuranosyl-
as-Triazine-3,5(2H,4H)-dione, 2-β-D-ribofuranosyl-
2-(β-D-Ribofuranosyl)-1,2,4-triazine-3,5(2H,4H)-dione
6-phosphonouridine 5′-monophosphate
azauridine
azur
EINECS 200-199-6
ribo-Azauracil
2-((2R,3R,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2H--[1,2,4]triazine-3,5-dione
2-b-D-Ribofuranosyl-1,2,4-triazine-3,5(2H,4H)-dione
Description 6-Azuridine (6-Azauridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
Related Catalog
References

[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.  

Density 2.1±0.1 g/cm3
Melting Point 157-159 °C(lit.)
Molecular Formula C8H11N3O6
Molecular Weight 245.19
Exact Mass 245.064789
PSA 137.67000
LogP -1.96
Index of Refraction 1.795
Storage condition 2-8°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XY8575000
CHEMICAL NAME :
as-Triazine-3,5(2H,4H)-dione, 2-beta-D-ribofuranosyl-
CAS REGISTRY NUMBER :
54-25-1
BEILSTEIN REFERENCE NO. :
0032281
LAST UPDATED :
199709
DATA ITEMS CITED :
26
MOLECULAR FORMULA :
C8-H11-N3-O6
MOLECULAR WEIGHT :
245.22
WISWESSER LINE NOTATION :
T6NNVMVJ B- BT5OTJ CQ DQ E1Q

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
11250 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
3400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
2400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - quail
DOSE/DURATION :
>316 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
8 gm/kg/32D-I
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Blood - leukopenia Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
150 mg/kg
SEX/DURATION :
female 47 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
84 mg/kg
SEX/DURATION :
female 6-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
252 mg/kg
SEX/DURATION :
female 6-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - body wall
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
330 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
330 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
900 mg/kg
SEX/DURATION :
female 7-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
900 mg/kg
SEX/DURATION :
female 12-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
10 gm/kg
SEX/DURATION :
female 14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
6250 mg/kg
SEX/DURATION :
female 3-27 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
Specific locus test
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Mutation test systems - not otherwise specified
TYPE OF TEST :
Cytogenetic analysis

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
5 gm/kg
REFERENCE :
CEFYAD Ceskoslovenska Fysiologie. (Academia, Vodickova 40, 112 29 Prague 1, Czechoslovakia) V.1- 1952- Volume(issue)/page/year: 21,278,1972 *** REVIEWS *** TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975
Symbol GHS07 GHS08
GHS07, GHS08
Signal Word Warning
Hazard Statements H302-H312-H332-H351
Precautionary Statements P280
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xn: Harmful;
Risk Phrases R20/21/22
Safety Phrases S22-S36
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS XY8575000
2169-64-4 structure

2169-64-4

~93%

54-25-1 structure

54-25-1

Literature: Depelley, Jean; Granet, Robert; Kaouadji, Mourad; Krausz, Pierre; Piekarski, Salomon; Delebassee, Sylvie; Bosgiraud, Claudine Nucleosides and Nucleotides, 1996 , vol. 15, # 5 p. 995 - 1008
59967-97-4 structure

59967-97-4

~88%

54-25-1 structure

54-25-1

Literature: Drasar, Pavel; Beranek, Jiri Collection of Czechoslovak Chemical Communications, 1987 , vol. 52, # 8 p. 2070 - 2082
461-89-2 structure

461-89-2

~%

54-25-1 structure

54-25-1

Literature: Collection of Czechoslovak Chemical Communications, , vol. 22, p. 1330 - 1332

Chemsrc provides CAS#:54-25-1 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 54-25-1 | Chemsrc address: https://m.chemsrc.com/en/baike/246414.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved